Company intelligence / Profile preview

Chengdu First Pharmaceutical

Ownership: Private
Development stage: Commercial

Overview

The company has developed small molecule drugs, with a focus on infectious and nervous system diseases. It has conducted at least two clinical trials, including a completed bioequivalence study comparing its oseltamivir phosphate granules to TAMIFLU® in healthy subjects. Some products have achieved regulatory approval outside China as early as December 1989 in Canada.

Therapeutic areas: OncologyEndocrinologyImmunologyHematologyNeurologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

4 assets

Fuqin Lotion

Preclinical

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Chengdu First Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chengdu First Pharmaceutical.

Explore the full profile